OMNICEF Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Omnicef, and when can generic versions of Omnicef launch?
Omnicef is a drug marketed by Abbvie and is included in two NDAs.
The generic ingredient in OMNICEF is cefdinir. There are twelve drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the cefdinir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Omnicef
A generic version of OMNICEF was approved as cefdinir by LUPIN on May 19th, 2006.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OMNICEF?
- What are the global sales for OMNICEF?
- What is Average Wholesale Price for OMNICEF?
Summary for OMNICEF
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 72 |
| Clinical Trials: | 14 |
| Patent Applications: | 7,046 |
| DailyMed Link: | OMNICEF at DailyMed |
Recent Clinical Trials for OMNICEF
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| St. Joseph's Hospital and Medical Center, Phoenix | Phase 4 |
| Thomas Jefferson University | Phase 4 |
| The Cleveland Clinic | Phase 4 |
US Patents and Regulatory Information for OMNICEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | OMNICEF | cefdinir | CAPSULE;ORAL | 050739-001 | Dec 4, 1997 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abbvie | OMNICEF | cefdinir | FOR SUSPENSION;ORAL | 050749-001 | Dec 4, 1997 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abbvie | OMNICEF | cefdinir | FOR SUSPENSION;ORAL | 050749-002 | Jul 29, 2004 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OMNICEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | OMNICEF | cefdinir | CAPSULE;ORAL | 050739-001 | Dec 4, 1997 | 4,935,507 | ⤷ Start Trial |
| Abbvie | OMNICEF | cefdinir | FOR SUSPENSION;ORAL | 050749-002 | Jul 29, 2004 | 4,935,507 | ⤷ Start Trial |
| Abbvie | OMNICEF | cefdinir | FOR SUSPENSION;ORAL | 050749-001 | Dec 4, 1997 | 4,935,507 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OMNICEF
See the table below for patents covering OMNICEF around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | H01250384 | NOVEL CRYSTAL OF 7-(2-(2-AMINOTHIAZOL-4-YL)-2-HYDROXYIMINOACETAMIDO)-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER) | ⤷ Start Trial |
| Canada | 1297096 | ACIDE 7-[2-(2-AMINOTHIAZOL-4-YL)-2- HYDROXYIMINOACETAMIDO]-3-VINYL-3-CEPHEM- 4-CARBOXYLIQUE (ISOMERE SYM), CRISTALLIN (CRYSTALLINE 7-[2-(2-AMINOTHIAZOL-4-YL)-2- HYDROXYIMINOACETAMIDO]-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER)) | ⤷ Start Trial |
| Ireland | 67348 | Novel crystalline 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) | ⤷ Start Trial |
| South Korea | 970008126 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch